Intrexon, ZIOPHARM partner to develop immunotherapies to treat GvHD
GvHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body. Under the new
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
In August, NYBC announced a partnership with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for the repair and
Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone is indicated to treat adult patients with multiple myeloma who have received at least one prior therapy. BLINCYTO (blinatumomab) can